Jecure Therapeutics Raises $20M From Versant Ventures

San Diego-based Jecure Therapeutics, a new startup focused on treatment of non-alcoholic steatohepatitis (NASH) and fibrosis of the liver, has raised $20M in a Series A funding round. The funding came from Versant Ventures, which launched the startup as its sole investor. Jecure's founders include CEO Jeffrey Stafford, PhD, and CSO James Veal, PhD, who previously were at Quanticel Pharmaceuticals (Acquried by Celgene in 2015). Quanticel Pharmaceuticals was also founded by Versant Ventures, and had been focused on cancer. The academic founder of Jecure is Ariel Feldstein, MD, Division Chief of Gastroenterology at the University of California, San Diego. More information »